These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
545 related articles for article (PubMed ID: 15710490)
21. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Iravani MM; Syed E; Jackson MJ; Johnston LC; Smith LA; Jenner P Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691 [TBL] [Abstract][Full Text] [Related]
22. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse. Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411 [TBL] [Abstract][Full Text] [Related]
23. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715 [TBL] [Abstract][Full Text] [Related]
24. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Kilbourn MR; Kuszpit K; Sherman P Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034 [TBL] [Abstract][Full Text] [Related]
25. A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl. Quinn LP; Perren MJ; Brackenborough KT; Woodhams PL; Vidgeon-Hart M; Chapman H; Pangalos MN; Upton N; Virley DJ J Neurosci Methods; 2007 Aug; 164(1):43-9. PubMed ID: 17498809 [TBL] [Abstract][Full Text] [Related]
26. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum. Singh S; Singh K; Gupta SP; Patel DK; Singh VK; Singh RK; Singh MP Brain Res; 2009 Aug; 1283():115-26. PubMed ID: 19520064 [TBL] [Abstract][Full Text] [Related]
27. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration. Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381 [TBL] [Abstract][Full Text] [Related]
28. Social odor recognition: a novel behavioral model for cognitive dysfunction in Parkinson's disease. Monaghan MM; Leddy L; Sung ML; Albinson K; Kubek K; Pangalos MN; Reinhart PH; Zaleska MM; Comery TA Neurodegener Dis; 2010; 7(1-3):153-9. PubMed ID: 20197696 [TBL] [Abstract][Full Text] [Related]
29. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility. Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726 [TBL] [Abstract][Full Text] [Related]
31. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity. Wu WR; Zhu XZ; Guan HJ; Wang RG; Ji XQ Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):146-50. PubMed ID: 10437162 [TBL] [Abstract][Full Text] [Related]
32. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758 [TBL] [Abstract][Full Text] [Related]
33. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Muñoz A; Rey P; Guerra MJ; Mendez-Alvarez E; Soto-Otero R; Labandeira-Garcia JL Neuropharmacology; 2006 Jul; 51(1):112-20. PubMed ID: 16678218 [TBL] [Abstract][Full Text] [Related]
34. Neuroprotection in Parkinson models varies with toxin administration protocol. Anderson DW; Bradbury KA; Schneider JS Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378 [TBL] [Abstract][Full Text] [Related]
35. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice. Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184 [TBL] [Abstract][Full Text] [Related]
36. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. Shin JY; Park HJ; Ahn YH; Lee PH J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187 [TBL] [Abstract][Full Text] [Related]
37. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. Rojo AI; Montero C; Salazar M; Close RM; Fernández-Ruiz J; Sánchez-González MA; de Sagarra MR; Jackson-Lewis V; Cavada C; Cuadrado A Eur J Neurosci; 2006 Oct; 24(7):1874-84. PubMed ID: 17067291 [TBL] [Abstract][Full Text] [Related]
38. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease. Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793 [TBL] [Abstract][Full Text] [Related]